Project Grant R50CA305191
Award Date 9/11/25
Completion Date 8/31/29
Dollars Obligated $424K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $361,695 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Oklahoma Health Sciences Center (OUHSC) for the period of September 1, 2025 to August 31, 2029. The grant aims to: 1) Leverage novel mHealth applications to boost enrollment in NCI-sponsored clinical trials, 2) Promote representative clinical trial enrollment from the local catchment area population, 3) Expand Veteran access to NCI trials, and 4)...
- This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
- The University of Southern California received a $650,450 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a novel lung cancer immunotherapy product. The grant will fund the translational development of a tumor-specific T cell receptor-engineered CD4+ T cell product targeting the CT83 cancer-testis antigen, which is expressed in 40-60% of non-small cell lung cancers. The project aims to improve the therapeutic potential of this...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $409,158 to the University of Missouri System to evaluate the effectiveness of an oncolytic adenovirus, OADSA-4-1BBL, alone or combined with anti-PD1 blockade in an immunocompetent lung cancer mouse model. The goal is to develop a novel oncolytic adenovirus that preferentially infects and kills lung cancer cells by targeting the transferrin receptor. The central hypothesis is that...
- This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to discover new therapeutic strategies for small cell lung cancer (SCLC). The $191,675 award to The University of Texas Southwestern Medical Center will investigate the role of Jumonji lysine demethylases (Jumonji KDMs) as potential druggable targets in SCLC, including for tumors that have developed resistance to standard chemotherapy. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- This Project Grant award, totaling $158,365, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to understand the impact of NRF2 activation on the initiation and progression of lung squamous cell carcinoma (LUSC). The primary awardee, the University of North Carolina at Chapel Hill, will develop a novel genetically-engineered mouse model to test how an activated NRF2 mutation affects LUSC incidence, tumor...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct research on uncovering the cellular and molecular drivers behind the aggressive metastatic potential of small cell lung cancer (SCLC). The project aims to leverage innovative human pluripotent stem cell-derived models of SCLC to gain deeper insights into this complex issue. By examining cell behavior in both primary tumors and...
- The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...